Drug Trial Radar · NCT04501666
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
286
Actual
Start
Sep 11, 2020
Primary completion
Nov 11, 2022
Study completion Feb 21, 2023
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
Conditions
- Prurigo Nodularis
Interventions
Nemolizumab 30 mgDrug
Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
PlaceboDrug
Participants received matching placebo as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16Time frame: Baseline, Week 16
- Number of Participants With an Investigator Global Assessment (IGA) Success at Week 16Time frame: Baseline, Week 16
Locations
100 sites in 10 countries. Site status is shown where the registry gives one.
Galderma Investigational Site
Birmingham, Alabama
Galderma Investigational Site
Birmingham, Alabama
Galderma Investigational Site
Los Angeles, California
Galderma Investigational Site
Sacramento, California
Galderma Investigational Site
San Diego, California
Galderma Investigational Site
San Diego, California
Galderma Investigational Site
Santa Monica, California
Galderma Investigational Site
Delray Beach, Florida
Galderma Investigational Site
Hollywood, Florida
Galderma Investigational Site
Largo, Florida
Galderma Investigational Site
Miami, Florida
Galderma Investigational Site
Pembroke Pines, Florida
Galderma Investigational Site
Tampa, Florida
Galderma Investigational Site
Columbus, Georgia
Galderma Investigational Site
Macon, Georgia
Galderma Investigational Site
Chicago, Illinois
Galderma Investigational Site
Lake Bluff, Illinois
Galderma Investigational Site
Topeka, Kansas
Galderma Investigational Site
Baltimore, Maryland
Galderma Investigational Site
Ann Arbor, Michigan
Galderma Investigational Site
Saint Joseph, Missouri
Galderma Investigational Site
St Louis, Missouri
Galderma Investigational Site
New York, New York
Galderma Investigational Site
High Point, North Carolina
Galderma Investigational Site
Raleigh, North Carolina
Galderma Investigational Site
Cleveland, Ohio
Galderma Investigational Site
Norman, Oklahoma
Galderma Investigational Site
Philadelphia, Pennsylvania
Galderma Investigational Site
Philadelphia, Pennsylvania
Galderma Investigational Site
Johnston, Rhode Island
Galderma Investigational Site
Providence, Rhode Island
Galderma Investigational Site
Knoxville, Tennessee
Galderma Investigational Site
Austin, Texas
Galderma Investigational Site
Bellaire, Texas
Galderma Investigational Site
Laredo, Texas
Galderma Investigational Site
Salt Lake City, Utah
Galderma Investigational Site
Springville, Utah
Galderma Investigational Site
Fairfax, Virginia
Galderma Investigational Site
Graz, Austria
Galderma Investigational Site
Linz, Austria
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.